Search Results - peter+collins

7 Results

Sort By:

Mononegavirales Vectors Expressing Chimeric Antigens

Human respiratory syncytial virus (RSV) continues to be the leading viral cause of severe acute lower respiratory tract disease in infants and children worldwide, and also is an important cause of morbidity and mortality in the elderly. A licensed vaccine or antiviral drug suitable for routine use remains unavailable. This invention relates to the use...

Published: 7/25/2024 | Inventor(s): Linda Brock, Ursula Buchholz, Peter Collins, Shirin Munir

Keywords(s): Added, Attenuated, DA4BXX, DA4XXX, DC5BXX, DC5XXX, DCXXXX, DD1XXX, DDXXXX, DEXXXX, DXXXXX, Expressing, F, Fusion, Gene, Highly, Human, Immunogenic, Macaques, MPV, Murine, PNEUMONIA, Protein, respiratory, RHESUS, RSV, Syncytial, virus

Category(s): Collaboration Sought > Collaboration, Application > Research Materials, Application > Diagnostics, Application > Vaccines, TherapeuticArea > Infectious Disease

Recombinant Chimeric Bovine/Human Parainfluenza Virus 3 Expressing SARS-CoV-2 Spike Protein and Its Use

Vaccines for SARS-CoV-2 are increasingly available under emergency use authorizations; however, indications are currently limited to individuals twelve (12) years or older. They also involve intramuscular immunization, which does not directly stimulate local immunity in the respiratory tract, the primary site of SARS-CoV-2 infection, shedding and spread....

Published: 7/25/2024 | Inventor(s): Shirin Munir, Cindy Luongo, Peter Collins, Cyril Le Nouen, Xueqiao Liu, Ursula Buchholz

Keywords(s): 2, ACUTE, Attenuated, B/HPIV3, BOVINE/HUMAN, chimeric, CORONAVIRUS, DC5BXX, DC5XXX, DCXXXX, DDXXXX, DEXXXX, DXXXXX, Expression, GLYCOPROTEIN, PIV3, respiratory, S, SARS-CoV-2, SEVERE, spike, Syndrome

Category(s): Collaboration Sought > Collaboration, TherapeuticArea > Infectious Disease, Application > Vaccines, Application > Research Materials

Improved Live-Attenuated Vaccine for Respiratory Syncytial Virus (RSV) Bearing Codon-Pair Deoptimized NS1, NS2, N, P, M and SH Genes and Additional Point Mutations in the P Gene

RSV is the most important viral agent of severe respiratory disease in infants and young children worldwide and also causes substantial morbidity and mortality in older adults. RSV is estimated to cause more than 33 million lower respiratory tract illnesses, three million hospitalizations, and nearly 200,000 childhood deaths worldwide annually, with...

Published: 7/25/2024 | Inventor(s): Cyril Le Nouen, Ursula Buchholz, Peter Collins

Keywords(s): ADDITIONAL, BEARING, Codonpair, DA4BXX, DA4XXX, DAXXXX, DC5BXX, DC5XXX, DCXXXX, DDXXXX, Deoptimized, DXXXXX, GENES, Improved, Live-Attenuated, M, Mutations, N, NS1, NS2, P, Pgene, POINT, respiratory, RSV, SH, Syncytial, Vaccine, virus

Category(s): Collaboration Sought > Collaboration, Application > Research Materials, Application > Diagnostics, Application > Vaccines, TherapeuticArea > Infectious Disease

Mononegavirales Vectors expressing Chimeric Antigens

Human respiratory syncytial virus (RSV) continues to be the leading viral cause of severe acute lower respiratory tract disease in infants and children worldwide. A licensed vaccine or antiviral drug suitable for routine use remains unavailable. This invention relates to the use of murine pneumonia virus (MPV), a virus to which humans normally are not...

Published: 7/25/2024 | Inventor(s): Peter Collins, Ursula Buchholz, Linda Brock, Shirin Munir

Category(s): Collaboration Sought > Collaboration, Application > Diagnostics, Application > Research Materials, Application > Vaccines, TherapeuticArea > Infectious Disease

Respiratory Syncytial Virus (RSV) Vaccines Based on Promoter-Proximate Attenuation

Available for licensing and commercial development is a patent estate and related biological materials for producing therapeutic or prophylactic vaccines against Respiratory Syncytial Virus (RSV). The claimed vaccine strategy relates to the engineering and creation of live-attenuated RSV vaccine candidates by shifting the position of one or more viral...

Published: 7/25/2024 | Inventor(s): Peter Collins, Brian Murphy, Ursula Buchholz, Stephen Whitehead, Christine Krempl

Keywords(s): ATTENUATE, Attenuated, ATTENUATING, ATTENUATION, Chromosome 7, monosomy, DC5BXX, DC5XXX, DCXXXX, Deletion 7, DXXXXX, GENES, Noonan syndrome, NS1, Promoter-proximal, RSV, RSV virus, RSV/PIV, Syncytial, Vaccine, Vaccine Design, VACCINE DEVELOPMENT, VACCINE VECTORS, vaccines, virus

Category(s): Collaboration Sought > Collaboration, Collaboration Sought > Licensing, TherapeuticArea > Infectious Disease, Application > Vaccines

Attenuated Human Parainfluenza Virus (PIV) for Use as Live, Attenuated Vaccines and as Vector Vaccines

The identified technologies describe self-replicating infectious recombinant paramyxoviruses with one or more attenuating mutations, such as a separate variant polynucleotide encoding a P protein and a separate monocistronic polynucleotide encoding a V protein, or at least one temperature sensitive mutation and one non-temperature sensitive mutation....

Published: 7/25/2024 | Inventor(s): Peter Collins, Sheila Nolan, Mario Skiadopoulos, Brian Murphy

Keywords(s): cDNA, CIS-ACTING, Complete, DC5BXX, DC5XXX, DCXXXX, Determination, DXXXXX, FOR..., FRAMES, Gene, Generate, Generation, Genomic, HPIV2, HPIV2., HPIV2/V94, Identification, MEASLES, Mumps, MUTATION, Novel, Nucleotide, Overlapping, P/V, Parainfluenza virus type 3, Parainfluenza virus type 3; Human parainfluenza virus type 3, Reading, recombinant, rHPIV2, Separated, sequence, Strain, UA1XXX, USEFUL, V94

Category(s): Collaboration Sought > Collaboration, Collaboration Sought > Licensing, TherapeuticArea > Rare / Neglected Diseases, Application > Vaccines, TherapeuticArea > Infectious Disease

Murine Monoclonal Antibodies Effective To Treat Respiratory Syncytial Virus

Available for licensing through a Biological Materials License Agreement are the murine MAbs described in Beeler et al, "Neutralization epitopes of the F glycoprotein of respiratory syncytial virus: effect of mutation upon fusion function," J Virol. 1989 Jul;63(7):2941-2950 (PubMed abs). The MAbs that are available for licensing are the following:...

Published: 7/25/2024 | Inventor(s): Peter Collins, Kathleen Coelingh, Robert Chanock (Estate), Brian Murphy, Judith Beeler

Keywords(s): #s, 1107;, 1112;, 1121;, 1129;, 1142;, 1153;, 1175-40; 1113-44; 1105-1, 1200;, 1214;, 1269, Cell, DB4BXX, DBXXXX, DXXXXX, Hybridoma, Lines, monoclonal

Category(s): Collaboration Sought > Licensing, Collaboration Sought > Materials Available, Application > Therapeutics, TherapeuticArea > Infectious Disease